Recombinant Klebsiella pneumoniae Prolipoprotein diacylglyceryl transferase (lgt)

What is Prolipoprotein diacylglyceryl transferase (Lgt) and what is its significance in bacterial pathogenesis?

Prolipoprotein diacylglyceryl transferase (Lgt) is a critical enzyme that catalyzes the first step in bacterial lipoprotein biogenesis by transferring a diacylglyceryl moiety from phosphatidylglycerol to the sulfhydryl group of the conserved cysteine residue in the lipobox of prolipoproteins. This modification anchors the prolipoproteins to the cell membrane, providing the foundation for subsequent processing steps. The significance of Lgt in bacterial pathogenesis is multifaceted and substantial, as it enables proper function of numerous lipoproteins involved in bacterial virulence.

Lipoproteins are a major category of bacterial surface proteins with diverse functions that significantly impact pathogen-host interactions during infection. Many lipoproteins serve as substrate-binding proteins for ABC transporters involved in the acquisition of essential nutrients including cations, sugars, amino acids, oligopeptides, polyamines, and minerals - all of which can be critical for full virulence . For example, in Streptococcus pneumoniae, deletion of specific lipoprotein-dependent transporters for manganese, zinc, or iron dramatically reduces virulence .

In addition to their metabolic roles, bacterial lipoproteins are key mediators of the inflammatory response through recognition by toll-like receptor 2 (TLR2), making Lgt indirectly important for host immune system interactions .

How does the deletion of lgt affect bacterial membrane integrity and permeability?

Deletion of lgt leads to significant alterations in bacterial membrane composition and integrity. Research on Lgt depletion in uropathogenic Escherichia coli demonstrates that loss of properly anchored lipoproteins results in:

• Permeabilization of the outer membrane

• Increased sensitivity to serum killing

• Enhanced susceptibility to antibiotics

• Altered membrane protein composition and localization

Studies specifically showed that Lgt depletion in E. coli leads to a significant loss of diacylglyceryl-modified pro-Lpp (DGPLP) and other peptidoglycan-linked Lpp forms in the peptidoglycan-associated protein (PAP) fractions, with a modest accumulation of unmodified pro-Lpp (UPLP) in the PAP fraction . This redistribution of lipoproteins significantly compromises the structural integrity of the cell envelope.

Analysis of membrane fractions reveals that without functional Lgt, prolipoproteins fail to be properly anchored to the membrane, leading to their mislocalization or secretion into the extracellular environment. The consequent membrane destabilization creates vulnerabilities that can be exploited by antimicrobial therapies or host defense mechanisms .

What experimental evidence supports Lgt as a potential antimicrobial target?

Multiple lines of experimental evidence validate Lgt as a promising antimicrobial target:

• Growth phenotypes: Lgt depletion significantly impairs bacterial growth and survival, demonstrating its essential nature for bacterial viability .

• Membrane integrity: Lgt inhibition leads to permeabilization of bacterial membranes, increasing susceptibility to antibiotics that would otherwise be excluded by intact membrane barriers .

• Serum sensitivity: Bacteria with depleted Lgt show increased sensitivity to killing by serum components, indicating compromised defense against host immune mechanisms .

• Lipoprotein processing: Biochemical analysis confirms that Lgt inhibition results in the accumulation of unmodified prolipoproteins, verifying the specific molecular mechanism of action .

• Novel inhibitors: Recently identified Lgt inhibitors demonstrate potent in vitro activity against the purified enzyme and bactericidal activity against wild-type Acinetobacter baumannii and E. coli strains .

• Resistance mechanisms: Unlike inhibitors of downstream lipoprotein biosynthesis steps, deletion of the major outer membrane lipoprotein (lpp) is not sufficient to rescue growth after Lgt depletion or provide resistance to Lgt inhibitors, suggesting that resistance development may be more difficult .

This multifaceted evidence indicates that Lgt inhibition affects multiple bacterial processes simultaneously, making it a potentially valuable antimicrobial target with a high barrier to resistance development.

What are effective methods for detecting Lgt inhibition in bacterial cells?

Detection of Lgt inhibition in bacterial cells requires methodologies that can track the processing and localization of lipoproteins. Based on current research protocols, the following methods have proven effective:

• Western blot analysis of lipoprotein processing:

  • Detection of accumulating pro-lipoprotein forms can be achieved by SDS-PAGE followed by immunoblotting using antibodies against specific lipoproteins .

  • The unmodified pro-Lpp (UPLP) form, which is the substrate of Lgt, accumulates when Lgt is inhibited or depleted .

• SDS fractionation to separate peptidoglycan-associated proteins:

  • Cell lysates can be centrifuged to separate SDS-insoluble peptidoglycan-associated proteins (PAP) from SDS-soluble non-PAP .

  • This allows tracking of various lipoprotein forms and their subcellular localization.

• Membrane permeability assays:

  • Assessing the uptake of compounds normally excluded by intact membranes (e.g., fluorescent dyes like propidium iodide) can indirectly indicate Lgt inhibition .

• Serum sensitivity tests:

  • Increased killing by serum components serves as a functional readout of compromised membrane integrity due to Lgt inhibition .

• Antibiotic susceptibility testing:

  • Enhanced sensitivity to antibiotics, particularly those that normally have limited penetration, provides evidence of Lgt inhibition .

The most definitive evidence comes from combining these approaches to demonstrate both the biochemical consequences (accumulation of unmodified prolipoproteins) and functional outcomes (membrane permeability, antibiotic susceptibility) of Lgt inhibition.

How can researchers validate the specificity of potential Lgt inhibitors?

Validating the specificity of potential Lgt inhibitors requires a multifaceted approach to distinguish on-target effects from non-specific activities:

• Biochemical enzyme assays:

  • Direct measurement of Lgt enzymatic activity in vitro using purified recombinant enzyme and defined substrates .

  • Determination of IC50 values and enzyme kinetics in the presence of inhibitors.

• Accumulation of specific lipoprotein intermediates:

  • Western blot analysis to detect accumulation of unmodified pro-Lpp (UPLP), which is the hallmark of specific Lgt inhibition .

  • Comparison with the accumulation patterns seen with genetic depletion of Lgt.

• Genetic validation approaches:

  • Testing inhibitors in strains with inducible Lgt expression to demonstrate correlation between inhibitor sensitivity and Lgt levels .

  • Attempting to generate resistant mutants and mapping mutations to the Lgt gene or related pathways.

• Comparative analysis with inhibitors of other lipoprotein processing enzymes:

  • Comparing phenotypic effects with those caused by inhibitors of LspA or LolCDE to identify unique signatures of Lgt inhibition .

  • Lgt inhibition should specifically lead to accumulation of unmodified prolipoproteins, while LspA inhibition leads to accumulation of diacylglyceryl-modified pro-Lpp (DGPLP) .

• Controls to rule out non-specific membrane effects:

  • Testing activity against membrane proteins unrelated to the lipoprotein pathway.

  • Assessing general membrane integrity parameters to distinguish specific lipid modification inhibition from general membrane disruption.

Research data has demonstrated that true Lgt inhibitors produce a distinct phenotypic profile that mirrors genetic Lgt depletion, including decreased peptidoglycan-associated lipoproteins and accumulation of unmodified prolipoproteins .

What assays can be used to measure Lgt enzymatic activity in vitro?

Measuring Lgt enzymatic activity in vitro requires specialized assays that track the transfer of diacylglyceryl groups to prolipoprotein substrates. The following assays have been developed for this purpose:

• Radiolabeled lipid substrate incorporation assay:

  • Using [³H] or [¹⁴C]-labeled phospholipids as donors and monitoring their transfer to purified prolipoprotein substrates.

  • Separation of products by SDS-PAGE and detection by fluorography or scintillation counting.

• Fluorescence-based assays:

  • Utilizing fluorescently labeled prolipoprotein substrates and monitoring changes in fluorescence properties upon diacylglyceryl modification.

  • Can be adapted for high-throughput screening of inhibitors.

• HPLC/MS-based quantification:

  • Analysis of reaction products by high-performance liquid chromatography coupled with mass spectrometry.

  • Allows precise quantification of modified and unmodified forms of the prolipoprotein substrate.

• Western blot-based mobility shift assays:

  • Exploiting the differential migration of modified and unmodified forms of prolipoproteins on SDS-PAGE.

  • Detection with antibodies specific to the prolipoprotein of interest.

When developing these assays for Klebsiella pneumoniae Lgt, researchers should consider:

• Selection of appropriate prolipoprotein substrates (ideally K. pneumoniae-derived)

• Optimization of reaction conditions (pH, temperature, ionic strength)

• Inclusion of appropriate detergents to solubilize the enzyme while maintaining activity

• Development of robust positive and negative controls

Research has successfully applied these approaches to identify novel Lgt inhibitors with potent activity against the purified enzyme and bactericidal effects against wild-type bacteria .

How does hypervirulent K. pneumoniae differ from classical strains in terms of lipoprotein expression and function?

Hypervirulent Klebsiella pneumoniae (hvKp) strains represent a significant evolutionary shift from classical K. pneumoniae (cKp), with notable differences in their lipoprotein profiles and associated functions:

Hypervirulent K. pneumoniae strains have emerged as a major global health concern, capable of causing severe tissue-invasive infections even in otherwise healthy individuals. These strains differ substantially from classical K. pneumoniae, which typically only infects immunocompromised hosts in healthcare settings .

While research specifically comparing lipoprotein expression between hvKp and cKp is still developing, several important differences have been observed:

• Virulence factor expression:

  • Hypervirulent strains often possess additional virulence factors, many of which may be lipoproteins or regulated by lipoprotein-dependent systems.

  • These include factors involved in iron acquisition, capsule production, and immune evasion .

• Metabolic adaptability:

  • Hypervirulent strains show enhanced ability to acquire essential nutrients in diverse host environments, potentially through upregulation of specific lipoprotein-dependent ABC transporters.

• Immune interaction:

  • Differences in lipoprotein expression may contribute to modified TLR2 activation patterns, potentially allowing hypervirulent strains to evade immune detection or modulate inflammatory responses.

• Antibiotic resistance mechanisms:

  • Recent reports indicate increasing acquisition of antibiotic resistance determinants by hypervirulent strains, creating "true and dreaded superbugs" .

  • This raises concerns about potential alterations in lipoprotein-dependent efflux systems or membrane permeability.

The alarming convergence of hypervirulence with multi-drug resistance in K. pneumoniae underscores the importance of understanding lipoprotein biology in these strains, as this may reveal novel therapeutic vulnerabilities .

What factors should be considered when designing Lgt inhibitors as potential antimicrobials against K. pneumoniae?

Designing effective Lgt inhibitors against K. pneumoniae requires consideration of multiple factors to ensure potency, selectivity, and resistance prevention:

• Structural considerations:

  • Target the catalytic site of Lgt based on structural studies or homology modeling

  • Consider species-specific differences in Lgt structure between K. pneumoniae and other bacteria

  • Design inhibitors that engage conserved catalytic residues while exploiting unique features of K. pneumoniae Lgt

• Selectivity profile:

  • Ensure specificity for bacterial Lgt without affecting mammalian lipid-modifying enzymes

  • Consider selectivity against specific bacterial species if narrow-spectrum activity is desired

  • Screen for off-target effects against other bacterial enzymes

• Pharmacokinetic properties:

  • Design molecules with appropriate membrane permeability to reach the inner membrane where Lgt is located

  • Consider efflux susceptibility, particularly important for K. pneumoniae which often expresses multiple efflux pumps

  • Optimize for stability in bacterial and host environments

• Resistance development:

  • Research indicates that inhibition of Lgt may be less susceptible to common resistance mechanisms that invalidate inhibitors of downstream steps in lipoprotein biosynthesis

  • Target conserved features of Lgt to raise the barrier to resistance development

  • Consider combination approaches with other antibiotics to prevent resistance emergence

• Efficacy against hypervirulent strains:

  • Ensure activity against hypervirulent K. pneumoniae strains that pose the greatest clinical threat

  • Test efficacy in models that reflect the tissue-invasive nature of hypervirulent infections

  • Validate activity against strains with acquired antimicrobial resistance determinants

Recent research has identified the first Lgt inhibitors that potently inhibit Lgt biochemical activity in vitro and show bactericidal activity against wild-type bacteria, providing promising starting points for development of K. pneumoniae-targeted Lgt inhibitors .

How do the phenotypes of lgt deletion differ between laboratory and clinical isolates of K. pneumoniae?

The phenotypic consequences of lgt deletion or inhibition can vary significantly between laboratory-adapted strains and clinical isolates of K. pneumoniae, with important implications for therapeutic development:

• Virulence factor expression:

  • Clinical isolates often express a different repertoire of virulence factors compared to laboratory strains, many dependent on properly functioning lipoproteins

  • Hypervirulent clinical isolates may show distinct phenotypic changes upon lgt deletion compared to classical strains

• Stress response systems:

  • Clinical isolates typically possess more robust stress response mechanisms that may partially compensate for lipoprotein processing defects

  • This can result in less pronounced growth defects in some clinical isolates compared to laboratory strains

• Membrane composition adaptations:

  • Clinical isolates may have adapted their membrane composition to various environmental pressures, potentially affecting the consequences of lipoprotein mislocalization

  • These adaptations might include alterations in phospholipid composition, outer membrane protein expression, or cell wall structure

• Antibiotic susceptibility profiles:

  • While lgt deletion generally increases antibiotic susceptibility, the magnitude of this effect may differ between clinical and laboratory isolates

  • Hypervirulent or multidrug-resistant clinical isolates might show unique patterns of sensitization to specific antibiotic classes

• Host interaction phenotypes:

  • Clinical isolates are selected for effective host interaction, potentially leading to different immune evasion consequences when lgt is deleted

  • Serum resistance, phagocytosis susceptibility, and inflammatory response induction may show strain-specific patterns

These differences highlight the importance of validating lgt inhibition as a therapeutic approach across a panel of clinically relevant isolates, particularly including hypervirulent strains that represent the greatest threat to public health . Research protocols should incorporate both laboratory and clinical strains to ensure comprehensive phenotypic characterization.

How can researchers distinguish between direct effects of Lgt inhibition and secondary phenotypic changes?

Distinguishing primary from secondary effects of Lgt inhibition requires careful experimental design and data analysis:

• Temporal analysis:

  • Monitor phenotypic changes over time following Lgt inhibition or depletion

  • Primary effects should emerge rapidly, while secondary consequences develop progressively

  • Example: Western blot analysis can show prolipoprotein accumulation (primary effect) occurring before membrane permeabilization (secondary effect)

• Correlation with biochemical markers:

  • Correlate phenotypic changes with direct biochemical evidence of Lgt inhibition

  • Primary effects should show strong temporal and dose-dependent correlation with prolipoprotein accumulation

  • Research shows that accumulation of unmodified pro-Lpp (UPLP) is a direct marker of Lgt inhibition

• Genetic complementation approaches:

  • Use conditional expression systems to rapidly restore Lgt function after inhibition

  • Primary effects should reverse quickly upon Lgt restoration, while secondary effects may persist

  • Complementation with variant Lgt proteins can help map specific functions to observed phenotypes

• Comparative analysis with other lipoprotein pathway inhibitions:

  • Compare Lgt inhibition phenotypes with those resulting from inhibition of other lipoprotein processing enzymes (LspA, LolCDE)

  • Effects specific to Lgt inhibition rather than general lipoprotein disruption can be identified

  • Research demonstrates distinct phenotypic signatures for each enzyme in the pathway

• Lipoprotome analysis:

  • Comprehensive proteomic analysis of lipoprotein processing state and localization

  • Identify which lipoproteins are most affected by Lgt inhibition

  • Link specific lipoprotein misprocessing to observed phenotypes

Research has shown that deletion of the major outer membrane lipoprotein (lpp) is not sufficient to rescue growth after Lgt depletion, indicating that the growth inhibition phenotype results from misprocessing of multiple lipoproteins rather than a single lipoprotein .

What are the potential compensatory mechanisms that might emerge following Lgt inhibition in K. pneumoniae?

Long-term Lgt inhibition may trigger various compensatory mechanisms in K. pneumoniae as the bacteria attempt to maintain membrane integrity and function:

• Membrane composition remodeling:

  • Alterations in phospholipid composition to stabilize membranes in the absence of properly anchored lipoproteins

  • Increased expression of non-lipoprotein membrane proteins to compensate for missing lipoproteins

  • Modifications to peptidoglycan structure to maintain cell envelope integrity

• Alternative nutrient acquisition systems:

  • Upregulation of non-lipoprotein-dependent transporters to compensate for compromised ABC transporters

  • Enhanced expression of siderophores or other nutrient-scavenging molecules

  • Metabolic rewiring to reduce dependence on nutrients typically acquired through lipoprotein-dependent systems

• Stress response activation:

  • Induction of envelope stress responses (e.g., σE pathway) to mitigate membrane damage

  • Upregulation of chaperones and proteases to handle misfolded prolipoproteins

  • Enhanced expression of efflux pumps to remove potentially toxic accumulated prolipoproteins

• Virulence adaptation:

  • Modification of virulence strategies to compensate for lipoprotein-dependent virulence factor impairment

  • Potential enhancement of other virulence mechanisms to maintain pathogenicity

  • Especially relevant for hypervirulent strains that may possess redundant virulence systems

• Genomic adaptations:

  • Mutations in prolipoprotein signal peptides to allow alternative processing

  • Alterations in genes controlling membrane homeostasis

  • Potential emergence of suppressor mutations in other lipoprotein processing pathway components

Research suggests that unlike inhibition of other steps in lipoprotein biosynthesis, deletion of the major outer membrane lipoprotein (lpp) is not sufficient to provide resistance to Lgt inhibitors, indicating that compensatory mechanisms may be more complex for Lgt inhibition .

How does Lgt inhibition impact different bacterial physiological processes in K. pneumoniae?

Lgt inhibition has far-reaching consequences across multiple bacterial physiological processes in K. pneumoniae due to the diverse functions of bacterial lipoproteins:

• Nutrient acquisition:

  • Impaired function of ABC transporters for essential nutrients including zinc, iron, and manganese

  • Compromised sugar transport systems, potentially affecting carbon source utilization

  • Studies in S. pneumoniae demonstrated that loss of Lgt affects cation-dependent ABC transporter functions

• Cell envelope integrity:

  • Permeabilization of the outer membrane, leading to increased susceptibility to antimicrobials

  • Altered peptidoglycan-lipoprotein interactions affecting cell wall stability

  • Research shows Lgt depletion leads to significant loss of peptidoglycan-associated lipoproteins

• Stress responses:

  • Enhanced sensitivity to environmental stresses (oxidative, pH, osmotic)

  • Altered ability to adapt to nutrient limitation or host defense mechanisms

  • Compromised response to envelope stress due to mislocalization of stress sensors

• Virulence expression:

  • Impaired expression or function of lipoprotein-dependent virulence factors

  • Potentially greater impact on hypervirulent strains that rely on specific virulence mechanisms

  • Increased sensitivity to serum killing due to compromised outer membrane integrity

• Antibiotic resistance:

  • Enhanced susceptibility to antibiotics that would normally be excluded by intact membranes

  • Possible impacts on efflux pump assembly or function

  • Particular concern for carbapenem-resistant hypervirulent strains

• Host interaction:

  • Altered TLR2 activation patterns affecting host inflammatory response

  • Changed recognition by host immune factors

  • Modified biofilm formation affecting persistence in host environments

The multifaceted impact of Lgt inhibition makes it a potentially powerful antimicrobial approach, particularly against hypervirulent and drug-resistant K. pneumoniae strains that pose the greatest clinical challenges .

What are the key research gaps in understanding Lgt function in hypervirulent K. pneumoniae?

Despite progress in understanding bacterial lipoprotein processing, several critical knowledge gaps remain regarding Lgt function specifically in hypervirulent K. pneumoniae:

• Structural characterization:

  • The three-dimensional structure of K. pneumoniae Lgt has not been fully characterized

  • Understanding structural differences between classical and hypervirulent strain Lgt proteins

  • Identification of potential unique binding sites for selective inhibitor design

• Hypervirulence-specific lipoproteins:

  • Comprehensive characterization of lipoproteins specifically associated with hypervirulence

  • Understanding how lipoprotein expression patterns differ between classical and hypervirulent strains

  • Determining which hypervirulence-associated lipoproteins are most critical for pathogenesis

• Host-pathogen interactions:

  • How lipoprotein processing affects recognition by host immune receptors

  • Whether hypervirulent strains exploit lipoprotein modifications to evade immunity

  • The impact of Lgt inhibition on hypervirulent strain interactions with host cells

• Metabolic dependencies:

  • Whether hypervirulent strains have unique lipoprotein-dependent metabolic pathways

  • How Lgt inhibition affects nutrient acquisition in diverse host environments

  • Potential metabolic vulnerabilities created by Lgt inhibition

• Resistance development:

  • The genetic barriers to resistance against Lgt inhibitors in hypervirulent strains

  • Whether hypervirulent strains develop different compensatory mechanisms compared to classical strains

  • Cross-resistance potential between Lgt inhibitors and existing antibiotics

• Carbapenem-resistant hypervirulent strains:

  • How the convergence of hypervirulence and carbapenem resistance affects lipoprotein processing

  • Whether these "true and dreaded superbugs" have altered Lgt expression or function

  • If Lgt inhibition remains effective against multidrug-resistant hypervirulent strains

Addressing these research gaps will be crucial for developing effective therapeutic strategies against the emerging threat of hypervirulent K. pneumoniae, particularly as these strains increasingly acquire resistance to "last resort" carbapenem antibiotics .

How might Lgt inhibitors be combined with existing antibiotics to enhance efficacy against resistant K. pneumoniae?

Lgt inhibitors present promising opportunities for combination therapy approaches against resistant K. pneumoniae strains:

• Membrane permeabilization synergy:

  • Lgt inhibition compromises outer membrane integrity, potentially enhancing penetration of antibiotics that normally have limited permeation

  • Particularly valuable for large or hydrophilic antibiotics like glycopeptides or β-lactams

  • Combination testing should evaluate concentration-dependent synergy to optimize dosing regimens

• Restoration of antibiotic sensitivity:

  • Lgt inhibition may partially overcome resistance mechanisms dependent on membrane integrity

  • Particularly relevant for carbapenem-resistant strains where impermeability contributes to resistance

  • Combinations with carbapenems could be especially valuable against the "true and dreaded superbugs" that combine hypervirulence with carbapenem resistance

• Multi-target approach to reduce resistance development:

  • Simultaneous targeting of Lgt and another essential pathway raises the genetic barrier to resistance

  • The distinct mechanism of Lgt inhibitors compared to conventional antibiotics makes cross-resistance less likely

  • Research suggests Lgt inhibition may be less prone to common resistance mechanisms affecting other lipoprotein pathway inhibitors

• Metabolic vulnerability exploitation:

  • Combining Lgt inhibitors with antibiotics targeting metabolic pathways dependent on lipoprotein-mediated nutrient acquisition

  • For example, targeting iron metabolism simultaneously with Lgt inhibition could create synergistic stress

• Host defense potentiation:

  • Lgt inhibition increases bacterial sensitivity to serum killing

  • Combinations with antibiotics that work optimally in the presence of host immune factors may show enhanced efficacy

  • Particularly relevant for tissue-invasive infections caused by hypervirulent strains

Experimental approaches should include:

• Checkerboard assays to identify synergistic combinations

• Time-kill studies to characterize killing dynamics

• In vivo models that reflect the tissue-invasive nature of hypervirulent infections

• Testing against diverse clinical isolates, particularly carbapenem-resistant hypervirulent strains

What methodological advances are needed to accelerate research on K. pneumoniae Lgt?

Advancing research on K. pneumoniae Lgt requires development of specialized tools and methodologies:

• Improved structural biology approaches:

  • Development of expression and purification protocols yielding stable, active K. pneumoniae Lgt

  • Crystallization conditions compatible with membrane proteins like Lgt

  • Cryo-EM methodologies adapted for lipoprotein processing enzymes

  • Computational models specifically validated for K. pneumoniae Lgt

• High-throughput screening systems:

  • Cell-based reporter assays specific for Lgt activity

  • Fluorescence-based enzymatic assays adaptable to automated screening platforms

  • Phenotypic screens that specifically detect Lgt inhibition in K. pneumoniae

  • Fragment-based screening approaches for novel inhibitor scaffolds

• Advanced genetic tools:

  • Inducible and tunable expression systems for Lgt in K. pneumoniae

  • CRISPR-Cas9 based genome editing optimized for hypervirulent strains

  • Transposon mutagenesis libraries in clinical isolates to identify genetic interactions with lgt

  • Reporter systems to monitor lipoprotein processing in real-time

• Lipidomic and proteomic methodologies:

  • Improved mass spectrometry approaches to characterize lipoprotein modifications

  • Methods to comprehensively identify and quantify all lipoproteins in K. pneumoniae

  • Techniques to distinguish correctly processed from misprocessed lipoproteins

  • Spatial proteomics to track lipoprotein localization following Lgt inhibition

• Infection models:

  • Animal models that recapitulate the tissue-invasive nature of hypervirulent K. pneumoniae infections

  • Cell culture systems to study host-pathogen interactions with Lgt-inhibited bacteria

  • Ex vivo tissue models to evaluate Lgt inhibitor efficacy in relevant microenvironments

  • Systems specifically designed to evaluate efficacy against carbapenem-resistant hypervirulent strains

• Computational approaches:

  • Machine learning algorithms to predict lipoprotein substrates most affected by Lgt inhibition

  • Molecular dynamics simulations of inhibitor-enzyme interactions

  • Systems biology approaches to model the effects of Lgt inhibition on bacterial physiology

  • Bioinformatic pipelines to analyze variations in Lgt and lipoproteins across K. pneumoniae strains

These methodological advances would significantly accelerate both fundamental research on K. pneumoniae Lgt and the development of Lgt-targeting therapeutics against this increasingly problematic pathogen.